JP2023538669A5 - - Google Patents
Info
- Publication number
- JP2023538669A5 JP2023538669A5 JP2023513103A JP2023513103A JP2023538669A5 JP 2023538669 A5 JP2023538669 A5 JP 2023538669A5 JP 2023513103 A JP2023513103 A JP 2023513103A JP 2023513103 A JP2023513103 A JP 2023513103A JP 2023538669 A5 JP2023538669 A5 JP 2023538669A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- formulation
- buffer
- antibody construct
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069432P | 2020-08-24 | 2020-08-24 | |
| US63/069,432 | 2020-08-24 | ||
| US202163197020P | 2021-06-04 | 2021-06-04 | |
| US63/197,020 | 2021-06-04 | ||
| PCT/US2021/047181 WO2022046651A1 (en) | 2020-08-24 | 2021-08-23 | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538669A JP2023538669A (ja) | 2023-09-08 |
| JP2023538669A5 true JP2023538669A5 (cg-RX-API-DMAC10.html) | 2024-08-30 |
Family
ID=78000768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513103A Pending JP2023538669A (ja) | 2020-08-24 | 2021-08-23 | Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤 |
Country Status (11)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL307677A (en) * | 2021-06-01 | 2023-12-01 | Amgen Inc | An accelerated method for preparing bleached protein formulations |
| AU2023343470A1 (en) * | 2022-09-14 | 2025-02-06 | Amgen Inc. | Bispecific molecule stabilizing composition |
| WO2025080688A1 (en) | 2023-10-12 | 2025-04-17 | Amgen Inc. | Compositions of bispecific antibody constructs to human dll3 and human cd3 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU2001264946A1 (en) | 2000-05-24 | 2001-12-03 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| CR20190408A (es) * | 2017-02-02 | 2020-01-31 | Amgen Inc | Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes |
| MA48763A (fr) * | 2017-05-05 | 2020-04-08 | Amgen Inc | Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés |
| KR20200036889A (ko) * | 2017-07-28 | 2020-04-07 | 에프. 호프만-라 로슈 아게 | 이중특이성 항체 제형 |
| EP3749363A1 (en) * | 2018-02-08 | 2020-12-16 | Amgen Inc. | Low ph pharmaceutical antibody formulation |
| HRP20260607T1 (hr) * | 2018-09-13 | 2026-06-05 | F. Hoffmann-La Roche Ag | Formulacija protutijela na csf-1r |
| WO2020072306A1 (en) * | 2018-10-01 | 2020-04-09 | Amgen Inc. | Methods for reducing aggregation of bispecific antibodies |
-
2021
- 2021-08-23 EP EP21783077.7A patent/EP4200333A1/en active Pending
- 2021-08-23 IL IL299242A patent/IL299242A/en unknown
- 2021-08-23 MX MX2023002280A patent/MX2023002280A/es unknown
- 2021-08-23 BR BR112023002923A patent/BR112023002923A2/pt unknown
- 2021-08-23 KR KR1020237009363A patent/KR20230058432A/ko active Pending
- 2021-08-23 CA CA3185960A patent/CA3185960A1/en active Pending
- 2021-08-23 WO PCT/US2021/047181 patent/WO2022046651A1/en not_active Ceased
- 2021-08-23 US US18/022,685 patent/US20230348596A1/en active Pending
- 2021-08-23 AU AU2021330845A patent/AU2021330845A1/en active Pending
- 2021-08-23 JP JP2023513103A patent/JP2023538669A/ja active Pending
-
2023
- 2023-02-17 CL CL2023000486A patent/CL2023000486A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7446356B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| EP1409018B1 (en) | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab | |
| JP6041673B2 (ja) | リポペプチド組成物および関連する方法 | |
| JP2023018090A (ja) | 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用 | |
| US20160375133A1 (en) | Methods for producing high concentration lyophilized pharmaceutical formulations | |
| JP2021512881A5 (cg-RX-API-DMAC10.html) | ||
| WO2010146598A2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| DK1993557T3 (en) | NOVEL epoprostenol DEFINITION AND MANUFACTURING METHOD THEREOF | |
| WO2011012637A4 (en) | Subcutaneous anti-her2 antibody formulation | |
| KR20090021298A (ko) | 항-ｅｇｆｒ 항체의 동결건조 제제 | |
| JP2013511557A5 (cg-RX-API-DMAC10.html) | ||
| US20090068196A1 (en) | Pharmaceutical formulation of an antibody against IL13Ralpha1 | |
| JP2005513110A (ja) | Ｅｇｆ受容体に対する抗体を含む凍結乾燥製剤 | |
| JP2012121894A (ja) | Ｉｌ−１アンタゴニスト製剤 | |
| JP2023539476A5 (cg-RX-API-DMAC10.html) | ||
| JP2024521329A5 (cg-RX-API-DMAC10.html) | ||
| JP2023524444A5 (cg-RX-API-DMAC10.html) | ||
| JP2023524445A5 (cg-RX-API-DMAC10.html) | ||
| US20040247588A1 (en) | Formulations of modified antibodies and methods of making the same | |
| JP2022518441A5 (cg-RX-API-DMAC10.html) | ||
| WO2000076480A2 (en) | Pharmaceutical materials and methods for their preparation and use | |
| JP2024523443A5 (cg-RX-API-DMAC10.html) | ||
| JP2025503483A5 (cg-RX-API-DMAC10.html) | ||
| RU2021107534A (ru) | Составы, содержащие антитела | |
| RU2024121592A (ru) | Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А |